Terms: = Kidney tumors AND TOP2A, TOP2, TP2A AND Treatment
12 results:
1. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
2. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
[TBL] [Abstract] [Full Text] [Related]
3. Identification of potential biomarkers associated with immune infiltration in papillary renal cell carcinoma.
Deng R; Li J; Zhao H; Zou Z; Man J; Cao J; Yang L
J Clin Lab Anal; 2021 Nov; 35(11):e24022. PubMed ID: 34606125
[TBL] [Abstract] [Full Text] [Related]
4. Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma.
Yin X; Wang Z; Wang J; Xu Y; Kong W; Zhang J
Oncoimmunology; 2021; 10(1):1933332. PubMed ID: 34262797
[TBL] [Abstract] [Full Text] [Related]
5. Influence of gene expression on survival of clear cell renal cell carcinoma.
Berglund A; Amankwah EK; Kim YC; Spiess PE; Sexton WJ; Manley B; Park HY; Wang L; Chahoud J; Chakrabarti R; Yeo CD; Luu HN; Pietro GD; Parker A; Park JY
Cancer Med; 2020 Nov; 9(22):8662-8675. PubMed ID: 32986937
[TBL] [Abstract] [Full Text] [Related]
6. LncRNA SNHG3 promotes clear cell renal cell carcinoma proliferation and migration by upregulating top2a.
Zhang C; Qu Y; Xiao H; Xiao W; Liu J; Gao Y; Li M; Liu J
Exp Cell Res; 2019 Nov; 384(1):111595. PubMed ID: 31505165
[TBL] [Abstract] [Full Text] [Related]
7. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma.
Luo Y; Shen D; Chen L; Wang G; Liu X; Qian K; Xiao Y; Wang X; Ju L
Aging (Albany NY); 2019 Aug; 11(16):6029-6052. PubMed ID: 31422942
[TBL] [Abstract] [Full Text] [Related]
8. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
[TBL] [Abstract] [Full Text] [Related]
9. Genetic and chromosomal alterations in Kenyan Wilms Tumor.
Lovvorn HN; Pierce J; Libes J; Li B; Wei Q; Correa H; Gouffon J; Clark PE; Axt JR; Hansen E; Newton M; O'Neill JA;
Genes Chromosomes Cancer; 2015 Nov; 54(11):702-15. PubMed ID: 26274016
[TBL] [Abstract] [Full Text] [Related]
10. Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway.
Toh YM; Li TK
Clin Cancer Res; 2011 Aug; 17(15):5026-37. PubMed ID: 21653687
[TBL] [Abstract] [Full Text] [Related]
11. Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population.
Pode-Shakked N; Metsuyanim S; Rom-Gross E; Mor Y; Fridman E; Goldstein I; Amariglio N; Rechavi G; Keshet G; Dekel B
J Cell Mol Med; 2009 Aug; 13(8B):1792-1808. PubMed ID: 20187302
[TBL] [Abstract] [Full Text] [Related]
12. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors.
Wittmann S; Wunder C; Zirn B; Furtwängler R; Wegert J; Graf N; Gessler M
Genes Chromosomes Cancer; 2008 May; 47(5):386-95. PubMed ID: 18260125
[TBL] [Abstract] [Full Text] [Related]
